Proietti Marco, Boriani Giuseppe
Department of Neuroscience, I Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
Institute of Cardiovascular Sciences, Universit of Birmingham, Birmingham, UK.
Ther Clin Risk Manag. 2018 Aug 22;14:1483-1488. doi: 10.2147/TCRM.S140377. eCollection 2018.
Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians. Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran. Idarucizumab was approved in 2015 by the US Food and Drugs Administration and European Medicines Agency for reversal of anticoagulation activity in dabigatrantreated patients. This review briefly summarizes the experimental evidence about effectiveness and safety of idarucizumab. Furthermore, we review the current recommendations and experts' point of view about the use of antidotes/reversal agents in patients reporting a major bleeding event.
在现实世界中，非维生素K拮抗剂口服抗凝药的使用正在不断普及。尽管如此，仍有多位医生表示对抗凝解毒剂/逆转剂有强烈需求。依达赛珠单抗是一种特异性结合达比加群的人源化单克隆抗体片段。2015年，依达赛珠单抗获美国食品药品监督管理局和欧洲药品管理局批准，用于逆转达比加群治疗患者的抗凝活性。本综述简要总结了关于依达赛珠单抗有效性和安全性的实验证据。此外，我们还综述了目前关于在发生重大出血事件的患者中使用解毒剂/逆转剂的建议和专家观点。
